Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk

Dow Jones

2024-11-21

0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

November 20, 2024 20:38 ET (01:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2485102008"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485102008\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485102008?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485102008","market":"sg","top_or_hot":-1,"title":"Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 20:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact of Sonova's Gains on Cochlear Are Unclear -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact of Sonova's Gains on Cochlear Are Unclear -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-21 09:38</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 20:38 ET (01:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485102008","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485102008","pubTimestamp":1732153080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD","BK7007":"医疗保健设备"},"translate_title":"索诺瓦的收益对耳蜗的影响尚不清楚——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":0.9},"content_text":"0138 GMT - It isn't clear to Citi analyst Mathieu Chevrier whether Sonova's share of the hearing-implant market is at the expense of Cochlear. He tells clients in a note that Sonova called out solid market-share gains as well as overall market growth in reporting 18% on-year growth in 1H sales. The increase is well above the 10% volume growth anticipated by Cochlear over its 2025 fiscal year, but Chevrier isn't sure what is behind the difference. It could be that overall market growth is unusually strong, or that the share is shifting from Cochlear or privately held Med-EI. Citi has a neutral rating and A$305.00 target price on Cochlear shares, which are down 0.3% at A$296.99. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 20:38 ET (01:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}